drugset / Trial / NCT00044655
Switching Medication to Treat Schizophrenia
Phase 4
Completed
219 enrolled
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
Timeline
- Start
- 2001-07
- Primary completion
- 2009-03
- Completion
- 2009-03
Publications
- Results Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.
- Results Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | — | — |
| Comparator | Olanzapine | Small molecule | — | — |
| Comparator | Quetiapine | Small molecule | — | — |
| Comparator | Risperidone | Other / unclassified | — | — |
| Comparator | Ziprasidone | Small molecule | — | — |